scholarly journals Antipyretic effect of myrcene (MCN) as a potential therapeutic alternative for the treatment of systemic inflammation response (SI) in euthermic rats model

2021 ◽  
Author(s):  
Maycon Emilio-Silva ◽  
Melina Zarricueta ◽  
Vinicius Rodrigues ◽  
Priscila Raimundo ◽  
Lúcia Regina da Rocha ◽  
...  
Keyword(s):  
Systemic Inflammation ◽  
Antipyretic Effect ◽  
Inflammation Response ◽  
Therapeutic Alternative

Prognostic value of the systemic inflammation response index (SIRI) before and after surgery in operable breast cancer patients

2020 ◽  
pp. 1-11
Author(s):  
Lei Wang ◽  
Yehui Zhou ◽  
Suhua Xia ◽  
Linlin Lu ◽  
Tiantian Dai ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Systemic Inflammation ◽  
Prognostic Value ◽  
Operable Breast Cancer ◽  
Breast Cancer Patients ◽  
Inflammation Response ◽  
Response Index ◽  
Before And After

scholarly journals The Influence of Systemic Inflammation Response Index on Survival Outcomes of Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Ahmet Kucuk ◽  
Emine Elif Ozkan ◽  
Sukran Eskici Oztep ◽  
Huseyin Mertsoylu ◽  
Berrin Pehlivan ◽  
...  
Keyword(s):  
Systemic Inflammation ◽  
Concurrent Chemoradiotherapy ◽  
Cohort Analysis ◽  
Prognostic Significance ◽  
Small Cell ◽  
Survival Outcomes ◽  
Small Cell Lung ◽  
Inflammation Response ◽  
Response Index ◽  
Limited Stage

Background. Recent studies have indicated that the systemic inflammation response index (SIRI) can efficiently predict survival outcomes in various tumor types. Thusly, in absence of comparable investigations in limited-stage small-cell lung cancers (LS-SCLCs), we aimed to retrospectively evaluate the prognostic utility of SIRI in LS-SCLC patients treated with concurrent chemoradiotherapy (CRT). Patients and Methods. Present multi-institutional retrospective analysis incorporated LS-SCLC patients treated with CRT at three academic radiation oncology centers between January 2007 and December 2018. The SIRI was calculated by using the peripheral blood neutrophil (N), monocyte (M), and lymphocyte (L) counts acquired in the last ≤7 days before the commencement of the CRT: SIRI = N × M/L. Accessibility of pretreatment SIRI cutoff that may stratify the study population into two gatherings with distinctive overall survival (OS) results was evaluated by utilizing the receiver operating characteristic (ROC) curve analysis. Primary objective was the association between the SIRI values and the OS results. Results. Search for the availability of an ideal SIRI cutoff that may stratify the entire patients’ population into two particular groups with distinctive OS outcomes identified the 1.93 value (area under the curve (AUC): 72.9%; sensitivity: 74.6%; specificity: 70.1%): Group 1: SIRI <1.93 (N = 71) and Group 2: SIRI ≥1.93 (N = 110), respectively. At a median follow-up of 17.9 (95% CI: 13.2–22.6) months, 47 (26.0%) patients were still alive (47.9% for SIRI <1.93 versus 18.3% for SIRI ≥1.93; p < 0.001 ). Kaplan–Meier comparisons between the two SIRI groups showed that the SIRI <1.93 cohort had significantly longer median OS (40.5 versus 14.2 months; p < 0.001 ) than the SIRI ≥1.93 cohort. Similarly, the 3- (54% versus 12.6%) and 5-year (33% versus 9.9%) OS rates were also numerically superior in the SIRI <1.93 cohort. Results of the multivariate analyses uncovered that the prognostic significance of the SIRI on OS outcomes was independent of the other confounding variables. Conclusions. The results of this retrospective multi-institutional cohort analysis suggested that a pre-CRT SIRI was a strong and independent prognostic biomarker that reliably stratified LS-SCLC patients into two cohorts with significantly different OS outcomes.

scholarly journals A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy

Cancer ◽  
2016 ◽  
Vol 122 (14) ◽  
pp. 2158-2167 ◽  
Author(s):  
Qi Qi ◽  
Liping Zhuang ◽  
Yehua Shen ◽  
Yawen Geng ◽  
Shulin Yu ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Systemic Inflammation ◽  
Inflammation Response ◽  
Response Index

scholarly journals Systemic inflammation response index (SIRI): A prognostic factor in pancreatic cancer (PC)

2017 ◽  
Vol 28 ◽  
pp. iii70
Author(s):  
Vilma Pacheco Barcia ◽  
Rebeca Mondéjar Solís ◽  
Olga Donnay Candil ◽  
Jacobo Rogado Revuelta ◽  
de la Maza López Olmedo Maria Dolores Fenor ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Prognostic Factor ◽  
Systemic Inflammation ◽  
Inflammation Response ◽  
Response Index

Risk factors of systemic inflammation response syndrome after endoscopic combined intrarenal surgery in the modified Valdivia position

2016 ◽  
Vol 23 (8) ◽  
pp. 687-692 ◽  
Author(s):  
Tadashi Tabei ◽  
Hiroki Ito ◽  
Kimitsugu Usui ◽  
Shinnosuke Kuroda ◽  
Takashi Kawahara ◽  
...  
Keyword(s):  
Risk Factors ◽  
Systemic Inflammation ◽  
Inflammation Response

scholarly journals Prognostic Values of Systemic Inflammation Response (SIR) Parameters in Resectable Cervical Cancer

Dose-Response ◽  
2019 ◽  
Vol 17 (1) ◽  
pp. 155932581982954
Author(s):  
Wen-Jie Wang ◽  
Ying Li ◽  
Jie Zhu ◽  
Min-jie Gao ◽  
Jian-ping Shi ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Systemic Inflammation ◽  
Inflammation Response

Prognostic value of preoperative systemic inflammation response index in patients with oral squamous cell carcinoma: Propensity score‐based analysis

Head & Neck ◽  
2020 ◽  
Vol 42 (11) ◽  
pp. 3263-3274 ◽  
Author(s):  
Jing Lin ◽  
Lin Chen ◽  
Qing Chen ◽  
Zhaocheng Zhuang ◽  
Xiaodan Bao ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Propensity Score ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Systemic Inflammation ◽  
Squamous Cell ◽  
Prognostic Value ◽  
Inflammation Response ◽  
Response Index
Sign in / Sign up

Export Citation Format

Share Document